Five years after a landmark US Supreme Court decision altered practices in eminent domain and economic development nationwide, a recent twist will have vindicated some people and burned others.  The pharmaceutical giant Pfizer Inc., which was the corporate anchor tenant in the middle of Kelo v. City of New London, has just announced they will vacate their 8-year old, 750,000 SF R&D campus in the Connecticut seaport city, and relocate the site’s 1,400 jobs to an owned facility just across the Thames River in Groton. 
After their $68 billion acquisition of rival Wyeth …